Babesiosis in the blood supply is a big problem.  This study was to determine the effectiveness of Enzyme Immunoassay (EIA).  The study, in Transfusion, showed that (EIA) for B. microti had a specificity in a non endemic population of 99.93%.  It had a sensitivity of 91.1% among clinical babesiosis patients who are IFA-positive, and is said to work well and is cost effective.  Levin, A. E., Williamson, P. C., Bloch, E. M., Clifford, J., Cyrus, S., Shaz, B. H., Kessler, D., Gorlin, J., Erwin, J. L., Krueger, N. X., Williams, G. V., Penezina, O., Telford, S. R., Branda, J. A., Krause, P. J., Wormser, G. P., Schotthoefer, A. M., Fritsche, T. R. and Busch, M. P. (2016), Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay. Transfusion. doi: 10.1111/trf.13618
This project was supported by the National Heart Lung and Blood Institute at the National Institutes of Health through SBIR Phase I and Phase II Contract HHSN268201000047C, and by Blood Systems Research Institute Contract 10734.

The tick-borne pathogen Babesia microti has become recognized as the leading infectious risk associated with blood transfusion in the United States, yet no Food and Drug Administration–licensed screening tests are currently available to mitigate this risk. The aim of this study was to evaluate the performance of an investigational enzyme immunoassay (EIA) for B. microti as a screening test applied to endemic and nonendemic blood donor populations.
The study aimed to test 20,000 blood donors from areas of the United States considered endemic for B. microti and 10,000 donors from a nonendemic area with the investigational B. microti EIA. Repeat-reactive samples were retested by polymerase chain reaction (PCR), blood smear, immunofluorescent assay (IFA), and immunoblot assay. In parallel, serum samples from symptomatic patients with confirmed babesiosis were tested by EIA, IFA, and immunoblot assays.
A total of 38 of 13,757 (0.28%) of the donors from New York, 7 of 4583 (0.15%) from Minnesota, and 11 of 8363 (0.13%) from New Mexico were found repeat reactive by EIA. Nine of the 56 EIA repeat-reactive donors (eight from New York and one from Minnesota) were positive by PCR. The specificity of the assay in a nonendemic population was 99.93%. Among IFA-positive clinical babesiosis patients, the sensitivity of the assay was 91.1%.
The B. microti EIA detected PCR-positive, potentially infectious blood donors in an endemic population and exhibited high specificity among uninfected and unexposed individuals. The EIA promises to provide an effective tool for blood donor screening for B. microti in a format amenable to high-throughput and cost-effective screening.

%d bloggers like this: